MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
14 Settembre 2023 - 1:30PM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED)
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that Robert Barrow, Chief Executive
Officer of MindMed, will participate in a panel at the TD Cowen 3rd
Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday,
September 20, 2023 at 11:00 a.m. ET, which is being hosted
virtually. The webcast of the panel discussion will be accessible
to those registered to attend the summit.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230914966700/en/
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA Vice President, Investor Relations and
Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Mag 2023 a Mag 2024
